natgillin/translations-raw huggingface dataset:
Solvent: 25 vials
Otapalo: 25 bočica
Solvent: 250 ml
Otapalo: 250 ml
Solvent: 3 ml solution supplied in a clear glass vial (5 ml, type I glass) with rubber stopper, aluminium seal and flip-off cap (polypropylene).
Otapalo: 3 ml otopine u bočici od prozirnog stakla (5 ml, staklo tipa I) s gumenim čepom, aluminijskim prstenom i poklopcem (polipropilen).
Solvent: 5 ml
Otapalo: 5 ml
Solvent: 5 ml of water for injections in a 6 ml vial (type I glass) with a stopper (fluoropolymer-coated chlorobutyl rubber) and flip-off cap (aluminium/plastic disc).
Otapalo: 5 ml vode za injekcije u bočici od 6 ml (staklo tipa I) s čepom (fluoropolimerom obložena klorobutilna guma) i „flip-off“ kapicom (aluminijski/plastični disk).
solvent: 5.0 ml (400 IU/ml)
otapalo: 5.0 ml (400 IU/ml)
solvent: 5.0 ml (600 IU/ml)
otapalo: 5.0 ml (600 IU/ml)
Solvent: 50 ml
Otapalo: 50 ml
Solvent: 500 ml
Otapalo: 500 ml
Solvent: 6 x 1 ml
Otapalo: 6 x 1 ml
Solvent: carmellose sodium sodium chloride polysorbate 20
Otapalo: karmelozanatrij natrijev klorid polisorbat 20
Solvent: chlorobutyl rubber stoppers and aluminium caps
Otapalo: klorobutilni gumeni čepovi i aluminijske kapice
Solvent: Clear, colourless solution
Otapalo: bistra, bezbojna otopina.
Solvent: Clear, colourless solution
Prašak: bijeli do bjelkasti prašak Otapalo: bistra, bezbojna otopina
Solvent: clear, colourless to slightly yellow solution.
Otapalo: bistra, bezbojna do svijetložuta otopina.
Solvent: colourless liquid
Otapalo: bezbojna tekućina
Solvent: Colourless type I glass bottle (10 ml) or Type II glass bottle (50 ml or 100 ml containing 60 ml of solvent) or PET bottles (10, 50 or 100 ml containing 60 ml of solvent) closed with a bromobutyl rubber closure and an aluminium cap.
Otapalo: bezbojna boca od stakla tipa I (10 ml) ili boca od stakla tipa II (50 ml ili 100 ml koja sadrži 60 ml otapala) ili PET boca (10, 50 ili 100 ml koja sadrži 60 ml otapala) zatvorena čepom od bromobutilne gume i aluminijskim zatvaračem.
Solvent: Contains calcium chloride dihydrate, sodium chloride, water for injection
Otapalo: sadrži kalcijev klorid dihidrat, natrijev klorid, vodu za injekcije
Solvent: Do not store above 25 °C.
Otapalo: ne čuvati iznad 25 °C.
Solvent: medium chain triglycerides.
Otapalo: trigliceridi srednje duljine lanca.
Solvent: methyl ethyl ketone (MEK)
Otapalo: Metiletilketon (MEK)
Solvent: Opalescent liquid.
Otapalo: opalescentna tekućina.
Solvent: pink colour with fine sediment
Otapalo: bjelkaste boje sa sitnim talogom.
Solvent: pink colour with fine sediment.
Otapalo: ružičaste boje s finim talogom.
Solvent: poloxamer 188, water for injection.
Otapalo: poloksamer 188, voda za injekciju
Solvent: pre-filled syringe (glass)
Otapalo: napunjena štrcaljka (staklo)
Solvent: Sodium chloride
Otapalo: natrijev klorid
Solvent: sodium chloride 9 mg/ml (0.9%) solution for injection.
Otapalo: 9 mg/ml (0,9%) otopina natrijevog klorida za injekciju.
Solvent: sodium chloride water for injections
Otapalo: natrijev klorid voda za injekcije
Solvent: Sodium chloride, water for injections
Otapalo: natrijev klorid, voda za injekcije
Solvent: Sucrose
Otapalo: Saharoza
Solvent: vial (PP)
Otapalo:
Solvent: water for injections
Otapalo: voda za injekcije.
Solvent: water for injections, a clear, colourless liquid.
Otapalo: voda za injekcije, bistra, bezbojna tekućina.
Solvent: whitish colour with fine sediment.
Otapalo: bjelkaste boje s finim talogom.
Solvent: whitish colour with fine sediment.
Otapalo: bjelkaste boje s sitnim talogom.
SOMAC Control contains the active substance pantoprazole, which blocks the ‘pump’ that produces stomach acid.
SOMAC Control sadrži djelatnu tvar pantoprazol, koja blokira „pumpu“ koja proizvodi želučanu kiselinu.
SOMAC Control is used for the short-term treatment of reflux symptoms (for example heartburn, acid regurgitation) in adults.
SOMAC Control se koristi za kratkotrajno liječenje simptoma refluksa (npr. žgaravica, vraćanje kiseline iz želuca) u odraslih.
Somatostatin analogues such as lanreotide and octreotide (used to treat acromegaly).
analoge somatostatina kao što su lanreotid i oktreotid (koriste se za liječenje akromegalije).
Somatostatin receptors are expressed in many tissues, especially in neuroendocrine tumours in which hormones are excessively secreted, including ACTH in Cushing’s disease.
Somatostatinski receptori izraženi su u mnogim tkivima, osobito u neuroendokrinim tumorima u kojima se prekomjerno izlučuju hormoni, uključujući ACTH u Cushingovoj bolesti.
Somatostatin receptors are expressed in many tissues, especially in neuroendocrine tumours in which hormones are excessively secreted, including GH in acromegaly.
Somatostatinski receptori izraženi su u mnogim tkivima, osobito u neuroendokrinim tumorima u kojima se prekomjerno izlučuju hormoni, uključujući GH kod akromegalije.
Somatropin (a growth hormone).
omatropin (hormon rasta).
Somatropin 3.3 mg (10 IU)/ml.
Somatropin 3,3 mg (10 IU)/ml.
Somatropin 6.7 mg (20 IU)/ml.
Somatropin 6,7 mg (20 IU)/ml.
Somatropin Biopartners 10 mg powder and solvent for prolonged-release suspension for injection
Somatropin Biopartners 10 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem
Somatropin Biopartners 10 mg: 10 mg (30 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a light-green flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in glass vial with a rubber stopper (butyl).
Somatropin Biopartners 10 mg: 10 mg (30 IU) somatropina u prašku u staklenoj bočici zatvorenoj gumenim čepom (butil) i svijetlozelenim „flip-off“ poklopcem (aluminij i plastika) i 1,5 ml otapala (trigliceridi srednje duljine lanca) u staklenoj bočici s gumenim (butilnim) čepom.
Somatropin Biopartners 10 mg: One vial of powder delivers 10 mg somatropin, corresponding to 30 IU.
Somatropin Biopartners 10 mg: Jedna bočica praška sadrži 10 mg somatropina, što odgovara 30 IU.
Somatropin Biopartners 2 mg powder and solvent for prolonged-release suspension for injection
Somatropin Biopartners 2 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem
Somatropin Biopartners 2 mg powder for prolonged-release suspension for injection somatropin
Somatropin Biopartners 2 mg prašak za suspenziju za injekciju s produljenim oslobađanjem somatropin
Somatropin Biopartners 2 mg: 2 mg (6 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a yellow flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in a glass vial with a rubber stopper (butyl).
Somatropin Biopartners 2 mg: 2 mg (6 IU) somatropina u prašku u staklenoj bočici zatvorenoj gumenim čepom (butil) i žutim „flip-off“ poklopcem (aluminij i plastika) i 1,5 ml otapala (trigliceridi srednje duljine lanca) u staklenoj bočici s gumenim (butilnim) čepom.
Somatropin Biopartners 2 mg: One vial of powder delivers 2 mg somatropin, corresponding to 6 IU.
Somatropin Biopartners 2 mg: Jedna bočica praška sadrži 2 mg somatropina, što odgovara 6 IU.
Somatropin Biopartners 20 mg powder and solvent for prolonged-release suspension for injection somatropin
Somatropin Biopartners 20 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem somatropin
Somatropin Biopartners 20 mg: 20 mg (60 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a green flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in glass vial with a rubber stopper (butyl).
Somatropin Biopartners 20 mg: 20 mg (60 IU) somatropina u prašku u staklenoj bočici zatvorenoj gumenim čepom (butil) i zelenim „flip-off“ poklopcem (aluminij i plastika) i 1,5 ml otapala (trigliceridi srednje duljine lanca) u staklenoj bočici s gumenim (butilnim) čepom.
Somatropin Biopartners 20 mg: One vial of powder delivers 20 mg somatropin, corresponding to 60 IU.
Somatropin Biopartners 20 mg: Jedna bočica praška sadrži 20 mg somatropina, što odgovara 60 IU.
Somatropin Biopartners 4 mg powder and solvent for prolonged-release suspension for injection
Somatropin Biopartners 4 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem
Somatropin Biopartners 4 mg powder for prolonged-release suspension for injection somatropin
Somatropin Biopartners 4 mg prašak za suspenziju za injekciju s produljenim oslobađanjem somatropin
Somatropin Biopartners 4 mg: 4 mg (12 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a pink flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in glass vial with a rubber stopper (butyl).
Somatropin Biopartners 4 mg: 4 mg (12 IU) somatropina u prašku u staklenoj bočici zatvorenoj gumenim čepom (butil) i ružičastim „flip-off“ poklopcem (aluminij i plastika) i 1,5 ml otapala (trigliceridi srednje duljine lanca) u staklenoj bočici s gumenim (butilnim) čepom.
Somatropin Biopartners 4 mg: One vial of powder delivers 4 mg somatropin, corresponding to 12 IU.
Somatropin Biopartners 4 mg: Jedna bočica praška sadrži 4 mg somatropina, što odgovara 12 IU.
Somatropin Biopartners 7 mg powder and solvent for prolonged-release suspension for injection
Somatropin Biopartners 7 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem
Somatropin Biopartners 7 mg powder for prolonged-release suspension for injection somatropin
Somatropin Biopartners 7 mg prašak za suspenziju za injekciju s produljenim oslobađanjem somatropin
Somatropin Biopartners 7 mg: 7 mg (21 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a light-blue flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in glass vial with a rubber stopper (butyl).
Somatropin Biopartners 7 mg: 7 mg (21 IU) somatropina u prašku u staklenoj bočici zatvorenoj gumenim čepom (butil) i svijetloplavim „flip-off“ poklopcem (aluminij i plastika) i 1,5 ml otapala (trigliceridi srednje duljine lanca) u staklenoj bočici s gumenim (butilnim) čepom.
Somatropin Biopartners 7 mg: One vial of powder delivers 7 mg somatropin, corresponding to 21 IU.
Somatropin Biopartners 7 mg: Jedna bočica praška sadrži 7 mg somatropina, što odgovara 21 IU.
Somatropin Biopartners has given rise to the formation of antibodies in approximately 4% of adult patients.
Somatropin Biopartners doveo je do razvoja protutijela u približno 4% odraslih bolesnika.
Somatropin Biopartners must not be used in patients with an active tumour or an acute life- threatening illness.
Somatropin Biopartners se ne smije koristiti kod bolesnika s aktivnim tumorom ili akutnom bolešću opasnom po život.
Somatropin Biopartners replaces the natural hormone.
Somatropin Biopartners zamjenjuje prirodni hormon.
Somatropin Biopartners should not be used in infants below the age of 2 years.
Somatropin Biopartners ne smije se primjenjivati u dojenčadi mlađe od 2 godine.
Somatropin Biopartners vial containing 1.5 mL solvent for suspension for injection
Somatropin Biopartners bočica koja sadrži 1,5 ml otapala za suspenziju za injekciju
Somatropin Biopartners vial containing active substance
Somatropin Biopartners bočica koja sadrži djelatnu tvar
Somatropin dose (mg)
Doza somatropina (mg)
Somatropin has been reported to reduce serum cortisol levels, possibly by affecting carrier proteins or by increased hepatic clearance.
Zabilježeno je da somatropin smanjuje vrijednosti kortizola u serumu, vjerojatno zbog utjecaja na prijenosne proteine ili zbog povećanja hepatičkog klirensa.
Somatropin induces the retention of sodium, potassium and phosphorus.
Somatropin potiče zadržavanje natrija, kalija i fosfora.
Somatropin is not recommended during pregnancy and should be discontinued if pregnancy occurs.
Somatotropin se ne preporučuje tijekom trudnoće te u slučaju iste treba prekinuti njegovu primjenu.
Somatropin must not be used for growth promotion in children with closed epiphyses.
Somatropin se ne smije primjenjivati za poticanje rasta u djece sa zatvorenim epifizama.
Somatropin must not be used when there is any evidence of tumour activity.
Somatropin ne smije se primijeniti kad postoji bilo kakav dokaz tumorske aktivnosti.
Somatropin must not be used when there is any evidence of tumour activity.
Somatropin se ne smije primijeniti kad postoji bilo kakav dokaz tumorske aktivnosti.
Somatropin must not be used when there is any evidence of tumour activity.
Somatropin se ne smije primjenjivati kod bilo kakvog dokaza tumorske aktivnosti.
Somatropin therapy should be continued in children and adolescents until their epiphysis are closed, or up to the time of renal transplantation.
Liječenje somatotropinom treba nastaviti kod djece i adolescenata sve dok se njihove epifize ne zatvore ili do trenutka transplantacije bubrega.
Somatropin therapy should be continued in children and adolescents until their epiphysis are closed.
Liječenje somatotropinom treba nastaviti kod djece i adolescenata sve do zatvaranja njihovih epifiza.
Somatropin treatment must not be started in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or to patients having acute respiratory failure or similar conditions.
Liječenje Somatropinom ne smije se započeti u bolesnika s akutnom kritičnom bolešću zbog komplikacija nakon otvorene operacije srca ili abodimena, višestrukih traumatskih ozljeda ili u bolesnika s akutnim respiratornim zatajenjem ili slična stanja.
Somatropin treatment must not be started in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or to patients having acute respiratory failure or similar conditions.
S liječenjem Somatropinom ne smije se započeti u bolesnika s akutnom kritičnom bolešću zbog komplikacija nakon otvorene operacije srca ili trbuha, višestrukim traumatskim ozljedama ili u bolesnika koji imaju akutno respiratorno zatajenje ili slična stanja.
Somatropin – a growth hormone.
omatropin – hormon rasta
SOMAVERT 10 mg and 15 mg
SOMAVERT 10 mg i 15 mg
SOMAVERT 10 mg powder and solvent for solution for injection SOMAVERT 15 mg powder and solvent for solution for injection SOMAVERT 20 mg powder and solvent for solution for injection SOMAVERT 25 mg powder and solvent for solution for injection SOMAVERT 30 mg powder and solvent for solution for injection Pegvisomant
SOMAVERT 10 mg prašak i otapalo za otopinu za injekciju SOMAVERT 15 mg prašak i otapalo za otopinu za injekciju SOMAVERT 20 mg prašak i otapalo za otopinu za injekciju SOMAVERT 25 mg prašak i otapalo za otopinu za injekciju SOMAVERT 30 mg prašak i otapalo za otopinu za injekciju pegvisomant
SOMAVERT 10 mg: One vial of powder contains 10 mg pegvisomant.
SOMAVERT 10 mg: jedna bočica s praškom sadrži 10 mg pegvisomanta.
SOMAVERT 15 mg: One vial of powder contains 15 mg pegvisomant.
SOMAVERT 15 mg: jedna bočica s praškom sadrži 15 mg pegvisomanta.
SOMAVERT 20 mg, 25 mg and 30 mg
SOMAVERT 20 mg, 25 mg i 30 mg
SOMAVERT 20 mg: One vial of powder contains 20 mg pegvisomant.
SOMAVERT 20 mg: jedna bočica s praškom sadrži 20 mg pegvisomanta.
SOMAVERT 25 mg: One vial of powder contains 25 mg pegvisomant.
SOMAVERT 25 mg: jedna bočica s praškom sadrži 25 mg pegvisomanta.
SOMAVERT 30 mg: One vial of powder contains 30 mg pegvisomant.
SOMAVERT 30 mg: jedna bočica s praškom sadrži 30 mg pegvisomanta.
Somavert has been studied in 112 patients with acromegaly in a 12-week study.
Somavert je ispitivan u 112 bolesnika s akromegalijom u ispitivanju od 12 tjedana.
Somavert is a powder and solvent that are mixed together to make up a solution for injection.
Somavert je dostupan obliku praška i otapala koji se zajedno miješaju da bi se dobila otopina za injekciju.
Somavert is given by injection under the skin.
Somavert se daje kao supkutana injekcija.
Somavert is used in patients who did not respond well to surgery and/or radiation therapy, and to treatment with somatostatin analogues (another type of medicine used in acromegaly).
Somavert se koristi u bolesnika koji nisu dobro odgovorili na kirurški zahvat i/ili terapiju zračenjem, kao ni na terapiju analozima somatostatina (drugom vrstom lijeka koji se koristi u slučaju akromegalije).
Somavert is used to treat adults with acromegaly (a rare hormonal disorder that usually occurs in middle-aged adults, which is caused by the pituitary gland producing excess growth hormone).
Somavert se koristi za liječenje odraslih osoba s akromegalijom (rijetkim hormonalnim poremećajem koji se obično javlja u sredovječnih odraslih osoba, a uzrokovan je prekomjernom količinom hormona rasta koji izlučuje hipofiza).
Somavert lowered IGF-I levels at all of the doses tested.
Somavert je snizio razine IGF-I u svim ispitanim dozama.
Somavert powder in vial with solvent in a pre-filled syringe pegvisomant for injection
Somavert prašak u bočici s otapalom u napunjenoj štrcaljki pegvisomant za injekciju
SOMAVERT should not be used during pregnancy unless clearly necessary (see section 4.4).
SOMAVERT se ne smije primjenjivati tijekom trudnoće osim ako je to nužno potrebno (vidjeti dio 4.4).
Some additional data have been obtained from a number of patients in a compassionate use programme.
Dobiveni su dodatni podaci od niza bolesnika u programu milosrdne primjene.
Some adult patients with HIV taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
U nekih se odraslih pacijenata s HIV-om koji uzimaju kombiniranu antiretrovirusnu terapiju može razviti koštana bolest koja se naziva osteonekrozom (odumiranje koštanog tkiva uzrokovano gubitkom dovoda krvi u kost).
Some adverse reactions (e.g. fatigue, asthenia, visual disturbances, dizziness) may impair patient’s ability to concentrate and react.
Neke nuspojave (npr. umor, astenija, smetnje vida, omaglica) mogu negativno utjecati na bolesnikovu sposobnost koncentracije i reakcije.
Some adverse reactions were also identified during post marketing surveillance.
Neke nuspojave bile su identificirane tijekom praćenja nakon stavljanja lijeka u promet.
Some animals may also not show titres > 0.5 IU/ml after single primary vaccination.
Isto tako, neke životinje nisu proizvele titar > 0,5 IJ/ml nakon primarnog cijepljenja jednom dozom.
Some animals may also not show titres > 0.5 IU/ml after single primary vaccination.
Isto tako, neke životinje nisu proizvele titar antitijela > 0,5 IJ/ml nakon primarnog cijepljenja jednom dozom.
Some anti-epileptic drugs known as enzyme inducers (carbamazepine, phenytoin, oxcarbazepine) have been shown to increase perampanel clearance and consequently to decrease plasma concentrations of perampanel.
Pokazalo se da neki antiepileptički lijekovi koji su poznati induktori enzima (karbamazepin, fenitoin, okskarbazepin), povećavaju klirens perampanela i posljedično snizuju koncentracije perampanela u plazmi.
Some antibiotics may need to be taken an hour before your Byetta injection.
Neke antibiotike ćete možda trebati uzimati jedan sat prije injekcije lijeka Byetta.
Some antibiotics, such as ciprofloxacin and tetracycline.
nekih antibiotika kao što su ciprofloksacin i tetraciklin;
Some antidepressant medicines like vortioxetine may reduce the quality of sperm in animals.
Neki antidepresivni lijekovi kao što je vortioksetin mogu smanjiti kakvoću sperme u životinja.
Some are skin coloured, others are greyish, pink, red or brown.
Može biti u boji kože, sivkasta, blago ružičasta, crvena ili smeđa.
Some are very common (may affect more than 1 in 10 people), some are common (may affect up to 1 in 10 people):
Neke su vrlo česte (mogu se javiti u više od 1 na 10 osoba), neke su česte (mogu se javiti u do 1 na 10 osoba):
Some bleeding events (MBEs/CRBEs; any bleeding) were significantly lower at a nominal alpha level of 5% in patients receiving dabigatran etexilate as compared with those receiving warfarin.
Pojedini događaji krvarenja (MBE-i/CRBE-i (engl. major bleeding events/ clinically relevant bleering events); svako krvarenje) bili su značajno manji na nominalnoj alfa-razini 5% kod bolesnika na dabigatraneeteksilatu u usporedbi sa bolesnicima na varfarinu.
Some bleeding events (MBEs/CRBEs; any bleeding) were significantly lower at a nominal alpha level of 5% in patients receiving dabigatran etexilate as compared with those receiving warfarin.
Pojedini događaji krvarenja (MBE-i/CRBE-i (engl. major bleeding events/clinically relevant bleeding events); svako krvarenje) bili su značajno manji na nominalnoj alfa-razini 5% kod bolesnika na dabigatraneteksilatu u usporedbi sa bolesnicima koji su primali varfarin.
Some cases also reported increases in blood urea nitrogen possibly due to hypoperfusion secondary to developing CHF (pre-renal azotaemia).
U nekim je slučajevima prijavljeno i povišenje razine dušika iz ureje u krvi, vjerojatno zbog hipoperfuzije kao posljedice razvoja kongestivnog zatajenja srca (prerenalna azotemija).
Some cases of severe vomiting were associated with
Neki su slučajevi teškog povraćanja bili povezani s
Some cases of splenic rupture were fatal (see section 4.4).
Neki slučajevi rupture slezene bili su smrtonosni (vidjeti dio 4.4).
Some cases of splenic rupture were fatal.
Neki slučajevi rupture slezene su imali smrtni ishod.
Some cases of splenic rupture were fatal.
Neki su slučajevi prsnuća slezene imali smrtni ishod.
Some cases of splenic rupture were fatal.
Pojedini slučajevi rupture slezene su imali smrtni ishod.
Some children and teenage patients who have received TNF-blockers such as Inflectra have developed cancers, including unusual types, which sometimes resulted in death.
U neke djece i mladih bolesnika koji su primali TNF-blokatore kakav je Inflectra razvio se rak, uključujući neuobičajene vrste raka koje su ponekad imale smrtni ishod.
Some children and teenage patients who have received TNF-blockers such as Remicade have developed cancers, including unusual types, which sometimes resulted in death.
U neke djece i mladih bolesnika koji su primali TNF-blokatore kao što je Remicade razvio se rak, uključujući neuobičajene vrste raka koje su ponekad imale smrtni ishod.
Some children and teenage patients who have received TNF-blockers such as Remsima have developed cancers, including unusual types, which sometimes resulted in death.
U neke djece i mladih bolesnika koji su primali TNF-blokatore kao što je Remsima razvio se rak, uključujući neuobičajene vrste raka koje su ponekad imale smrtni ishod.
Some children did not reach their projected height within 1-12 years after completing treatment.
Neka djeca nisu dostigla svoju planiranu visinu unutar 1–12 godina nakon završetka liječenja.
Some corticosteroids may cause sodium and water retention and hypokalaemia in long term use.
Pojedini kortikosteroidi mogu uzrokovati zadržavanje natrija i vode te hipokemiju pri dugotrajnoj primjeni.
Some cross-protection was observed against related H5N1 virus variants in clinical trials (see section 5.1).
U kliničkim je ispitivanjima primijećena križna zaštita protiv srodnih varijanti virusa H5N1 (vidjeti dio 5.1).
Some cross-protection was observed against related H5N1 virus variants in clinical trials (see section 5.1).
U kliničkim je ispitivanjima primijećena određena križna zaštita protiv srodnih varijanti virusa H5N1 (vidjeti dio 5.1).
Some dog breeds may present increased susceptibility to macrocyclic lactones, potentially leading to signs of neurotoxicity.
Neke pasmine pasa su osobito osjetljive na makrocikličke laktone koji mogu biti neurotoksični.
Some dogs do not need daily treatment; treatment every other day may be tried once the effective daily dose has been established.
Neki psi ne trebaju dnevni tretman, može se primijeniti tretman svaki drugi dan, nakon što je uspostavljena efektivna dnevna doza.
Some dogs do not need daily treatment; treatment every other day may be tried, once the effective daily dose has been established.
Neki psi ne trebaju dnevni tretman, može se primijeniti tretman svaki drugi dan, nakon što je uspostavljena djelotvorna dnevna doza.
Some effects mentioned under section 4.
Neke od nuspojava spomenutih u dijelu 4.
Some effects mentioned under section 4.
Neki učinci navedeni u dijelu 4.
Some effects mentioned under section 4.
Neki učinci spomenuti u dijelu 4.